Leqembi Five-Year Data: Gap Versus Untreated Alzheimer’s Decline Keeps Widening
Five years of continuous lecanemab left patients 2.05 CDR-SB points better than an untreated cohort, while ARIA risk fell after year one. What the CTAD 2026 data mean for Eisai and Biogen.
